Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain …
BACKGROUND In a phase 1 study of pulse/continuous‐dose erlotinib, no patient had
disease progression in the central nervous system (CNS). This expansion cohort of the …
disease progression in the central nervous system (CNS). This expansion cohort of the …
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain …
KC Arbour, MG Kris, GJ Riely, A Ni, K Beal, M Daras… - Cancer, 2017 - europepmc.org
Background In a phase 1 study of pulse/continuous-dose erlotinib, no patient had disease
progression in the central nervous system (CNS). This expansion cohort of the phase 1 …
progression in the central nervous system (CNS). This expansion cohort of the phase 1 …
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain …
KC Arbour, MG Kris, GJ Riely, A Ni, K Beal… - Cancer, 2018 - pubmed.ncbi.nlm.nih.gov
Background In a phase 1 study of pulse/continuous-dose erlotinib, no patient had disease
progression in the central nervous system (CNS). This expansion cohort of the phase 1 …
progression in the central nervous system (CNS). This expansion cohort of the phase 1 …
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain …
KC Arbour, MG Kris, GJ Riely, A Ni, K Beal… - …, 2018 - ohiostate.elsevierpure.com
BACKGROUND: In a phase 1 study of pulse/continuous-dose erlotinib, no patient had
disease progression in the central nervous system (CNS). This expansion cohort of the …
disease progression in the central nervous system (CNS). This expansion cohort of the …
Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain …
KC Arbour, MG Kris, GJ Riely, A Ni, K Beal, M Daras… - Cancer, 2017 - infona.pl
BACKGROUND In a phase 1 study of pulse/continuous‐dose erlotinib, no patient had
disease progression in the central nervous system (CNS). This expansion cohort of the …
disease progression in the central nervous system (CNS). This expansion cohort of the …
[引用][C] Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain …
KC Arbour, MG Kris, GJ Riely, A Ni, K Beal, M Daras… - Cancer, 2017 - cir.nii.ac.jp
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with
epidermal growth factor receptor-mutant lung cancers and brain metastases | CiNii Research …
epidermal growth factor receptor-mutant lung cancers and brain metastases | CiNii Research …